Abstracts tagged "Damage Index"

Abstract Number: 2058 • ACR Convergence 2025
Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort
valeria cantu¹, Emmanuel Dominguez-Chapa², Rebeca L. Polina-Lugo¹, Ana Cecilia Bardan Inchaustegui³, fernanda m. garcia-Carrillo⁴, Ericka S. Reyna-Hernandez⁵, Daniela A. Mejia-Rodriguez⁵, Rosa Arvizu-Rivera⁶, Jesus Alberto Cardenas-de la Garza⁷, Miguel Villarreal-Alarcón⁸ and Dionicio A. Galarza-Delgado⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁷Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁸Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare diseases that involve chronic muscle inflammation, weakness, and pain. Autoantibodies in IIM play a central role in disease…
Abstract Number: 2053 • ACR Convergence 2025
A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Agustin Hernández-López¹, Nancy R Mejía Domínguez², Yatzil Reyna Juárez³, María José Ostos Prado⁴, Beatriz Alcalá Carmona⁵, Jennifer Tiaré Balderas Miranda⁶, Carlos A. Núñez-Álvarez⁵, Marta E. Baños-Laredo⁷, Diana Gómez-Martín⁸ and Jiram Torres-Ruiz⁹, ¹Instituo Nacional de Ciencias Médicas y Nutricion Salvador Zubirán, Morelia, Michoacan de Ocampo, Mexico, ²Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁶Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁷INCMNSZ, Cdmx, Mexico, ⁸INCMNSZ, Mexico city, Federal District, Mexico, ⁹INCMNSZ, Ciudad de México, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by muscular inflammation that can affect any organ or system. Reported mortality rates…
Abstract Number: 1899 • ACR Convergence 2025
Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
Manuel Ugarte-Gil¹, Sarah Gasman², Federico Zazzetti³, Ashley Orillion², Anna Sheahan⁴, Clair Blacketer², Michel van Speybroeck⁵, Reyhan Sonmez⁶, Erika Noss², Rocío Gamboa-Cárdenas⁷, Víctor Pimentel-Quiroz⁸, Kaleb Michaud⁹, Patti Katz¹⁰, Rangi Kandane-Rathnayake¹¹, Eric Morand¹², Worawit Louthrenoo¹³, Alberta Hoi¹⁴, Yi-Hsing Chen¹⁵, Jiacai Cho¹⁶, Laniyati Hamijoyo¹⁷, Shue Fen Luo¹⁸, Sandra Navarra¹⁹, Mandana Nikpour²⁰, José María Pego-Reigosa²¹, Iñigo Rúa-Figueroa²², Zulema Plaza²³, Maria Galindo-Izquierdo²⁴, Julia Martínez Barrio²⁵, Jaime Calvo²⁶, Antonio Fernández-Nebro²⁷, Raúl Menor Almagro²⁸, EVA GLORIA TOMERO MURIEL²⁹, Javier Narváez³⁰ and Chetan S. Karyekar³¹, ¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ²Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, ⁵Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, ⁶Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, ⁷Universidad Científica del Sur, Lima, Peru, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰UCSF, San Rafael, CA, ¹¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹²Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ¹³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ¹⁴Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹⁵Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ¹⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ¹⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ¹⁸Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁹University of Santo Tomas, Manila, Philippines, ²⁰University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, ²¹Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ²⁴Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ²⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ²⁶Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ²⁷Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ²⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Johnson & Johnson, Spring House, PA, USA, Spring House
Background/Purpose: SLE is characterized by heterogeneous clinical presentation and periods of flare and remission, with variation in management globally. A goal for SLE management is…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1469 • ACR Convergence 2025
Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
Adriana Vázquez-Hernández¹, Emilio Godinez-Lazarini², Erik Cimé-Aké² and Hilda Fragoso-Loyo³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico
Background/Purpose: In systemic lupus erythematosus (SLE), differences have been observed between patients of different ages at onset. This study evaluates remission, low disease activity, and…
Abstract Number: 1425 • ACR Convergence 2025
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Pankti Mehta¹, Shangyi Gao², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is…
Abstract Number: 1154 • ACR Convergence 2025
Assessment Of Damage Using The IgG4-Related Disease Damage Index.
Eduardo Martin-Nares¹ and Gabriela Hernandez-Molina², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder affecting multiple organs, often leading to irreversible damage. Standardized tools like the IgG4-RD Damage Index (DI)…
Abstract Number: 0636 • ACR Convergence 2025
AA Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways
Sepehr Taghavi¹, Ines Silva², Jacob Vasquez³, Vasileios Kyttaris⁴, Tyler O'Malley⁵ and Mike Nerenberg⁶, ¹Exagen Inc, Escondido, CA, ²Exagen, Carlsbad, CA, ³Exagen, Inc., Vista, CA, ⁴Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵Exagen, Vista, CA, ⁶Exagen, DEL MAR, CA
Background/Purpose: Lupus nephritis (LN) and diabetic kidney disease (DKD) are leading causes of chronic kidney disease (CKD) that differ by age, sex, and underlying mechanisms.…
Abstract Number: 0608 • ACR Convergence 2025
Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
Elena Heras Recuero¹, Antia Garcia Fernandez², Cristina Gomez-Moreno³, Ivan Ferraz Amaro⁴, Javier Llorca⁵ and Miguel A. González-Gay⁶, ¹Hospital Fundacion Jimenez Dias, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ⁶Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
Abstract Number: 2515 • ACR Convergence 2025
The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
Ruoning Ni¹, Jessica L. Bloom², Kaci Pickett-Nairne², Lori Silveira³, Chao Zhang⁴, David Cuthbertson⁵, Thomas corbridge⁶, Nader Khalidi⁷, Curry Koening⁸, Carol McAlear⁹, Paul Monach¹⁰, Larry Moreland¹¹, Christian Pagnoux¹², Rennie Rhee⁹, Philip Seo¹³, Jared Silver⁶, Ulrich Specks¹⁴, Kenneth Warrington¹⁴, Michael Wechsler¹⁵, Carol Langford¹⁶, Peter Merkel⁹ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, ²University of Colorado, Denver, ³University of Colorado, Aurora, CO, ⁴Cleveland Clinic, Cleveland Heights, OH, ⁵University of South Florida, Tampa, ⁶US Medical Affairs Respiratory GSK, Durham, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁸University of Texas Dell Medical School, Austin, TX, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹University of Colorado, Denver, CO, ¹²Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶Cleveland Clinic, Moreland Hills, OH
Background/Purpose: Neurologic involvement (NI) is common in ANCA-associated vasculitis (AAV) and often irreversible. It is unknown whether patients with AAV and NI accumulate more damage…
Abstract Number: 0596 • ACR Convergence 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Diana Fernandez¹, Rosana Quintana², Karen Roberts³, Romina Nieto², Marina Scolnik⁴, Carmen Funes Soaje⁵, CINTIA OTADUY⁶, Veronica Saurit⁷, Valeria Arturi⁸, GUILLERMO ARIEL BERBOTTO⁹, Maria Constanza Bertolaccini¹⁰, Mario Eduardo Kerzberg¹¹, Maria de los Angeles Gargiulo¹², Cecilia Pisoni¹³, Ana Carolina Ralle¹⁴, Joaquín Martinez Serventi¹⁵, Ana Silva¹⁶, ODIRLEI MONTICIELO¹⁷, Henrique Mariz¹⁸, Laíssa Cristina Alves Alvino¹⁹, Eduardo Borba²⁰, Emily Figueiredo Neves Yuki²¹, Edgard Torres dos Reis-Neto²², Iris Guerra Herrera²³, Milena Mimica²⁴, Gustavo Aroca-Martínez²⁵, Antonio Iglesias-Gamarra²⁶, Carlos Alberto Cañas²⁷, Gerardo Quintana-Lopez²⁸, Carlos Toro-Gutierrez²⁹, Mario Moreno Alvarez³⁰, Olga-Lidia Vera-Lastra³¹, Margarita Portela Hernández³², Hilda Fragoso-Loyo³³, Luis H Silveira³⁴, Yelitza Gonzalez Bello³⁵, Carlos Abud-Mendoza³⁶, Jorge Antonio Esquivel Valerio³⁷, Marcelo Barrios³⁸, Lourdes Carolina Vázquez³⁹, Magaly Alva Linares⁴⁰, Manuel Ugarte-Gil⁴¹, Armando Calvo⁴², Roberto Muñoz-Louis⁴³, Ana Carina Pizzarossa⁴⁴, Gonzalo Silveira⁴⁵, Federico Zazzetti⁴⁶, Ashley Orillion⁴⁷, Urbano Sbarigia⁴⁸ and Guillermo Pons-Estel², ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ³Consultora externa de GLADEL, Rosario, Argentina, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Servicio de Reumatología Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁸Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ¹⁰Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹¹Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires; Buenos Aires, Argentina, Buenos Aires, Argentina, ¹³CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹⁴Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁵Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁶Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, ¹⁷Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁸Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁹Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, ²⁰Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ²²Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²³Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²⁴Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁵Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁶Universidad Nacional de Colombia, Barranquilla, Colombia, ²⁷Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁸Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁹Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ³⁰Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³¹División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, Mexico City, Mexico, ³²Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁵Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, ³⁶Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁷Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁸Hospital de Clínicas II, Uruguay, Uruguay, Uruguay, ³⁹Facultad de Ciencias Médicas. Universidad Nacional de Asunción-Paraguay, Paraguay, Asunción, Paraguay, ⁴⁰HOSPITAL EDGARDO REBAGLIATI MARTINS, San Borja, Peru, ⁴¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴²Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴³Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴⁴Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Facultad de Medicina - Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁶Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁸Johnson & Johnson, Beerse, Belgium

Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the…
Abstract Number: 2444 • ACR Convergence 2025
Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
Emily Gutowski¹, Jessica Dai², Erin Carter³, Brooke Cohen⁴, Jill Buyon⁵, Chung-E Tseng⁶, Mala Masson⁷, Amit Saxena⁵, H Michael Belmont⁸, Joseph Colcombe⁶, Yasha Modi³, Carol Lee⁶ and Peter Izmirly⁹, ¹New York University Grossman School of Medicine, Brooklyn, NY, ²New York University Grossman School of Medicine, Tenafly, NJ, ³New York University Grossman School of Medicine, New York, NY, ⁴Yale Physician Associate Program, New Haven, CT, ⁵NYU Grossman School of Medicine, New York, NY, ⁶New York University Grossman School of Medicine, New York, ⁷NYU Langone Health, New York, ⁸NYU School of Medicine, New York, NY, ⁹New York University Grossman School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone of systemic lupus erythematosus (SLE) management, but long-term use carries the risk of retinopathy. While prior studies have identified…
Abstract Number: 0552 • ACR Convergence 2025
Radiographic Sacroiliitis Progression in Psoriatic Arthritis
Virginia Carrizo Abarza¹, Pankti Mehta², Fadi Kharouf³, Shangyi Gao⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ³University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁴Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Radiographic sacroiliitis is an important indicator of axial involvement psoriatic arthritis (PsA), but only little is known about factors associated with progression of sacroiliitis.…
Abstract Number: 2422 • ACR Convergence 2025
Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
Oihane Ibarguengoitia-Barrena¹, Leyre Riancho Zarrabeitia², Iñigo Rúa-Figueroa³, Karen Roberts⁴, Victor Martinez-Taboada⁵, Raúl Menor Almagro⁶, Belén Serrano-Benavente⁷, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernández-Nebro¹⁰, Maria Esther Ruiz Lucea¹¹, Jaime Calvo¹², Jose Francisco Garcia Llorente¹³, EVA GLORIA TOMERO MURIEL¹⁴, Maria Esther Uriarte¹⁵, Mercedes Freire González¹⁶, Angela Pecondón-Español¹⁷, Javier García-Fernández¹⁸, Lorena Expósito-Pérez¹⁹, Monica Ibañez Barcelo²⁰, Elena Aurrecoechea²¹, Carlos Montilla²², Jose Rosas Gómez de Salazar²³, Maria Garcia-Villanueva²⁴, Rocío Caño²⁵, Francisco Javier Toyos²⁶, Francisco Javier Novoa²⁷, Clara Moriano²⁸, Gema Bonilla²⁹, Javier Narváez³⁰, Jose Luis Andreu³¹, Marta Arévalo-Salaet³², Loreto Horacda-Rubio³³, Tatiana Cobo-Ibáñez³⁴, Nuria Lozano Rivas³⁵, Cristina Bohorquez³⁶, Carlota Laura Iniguez Ubiaga³⁷, Eva salgado-Pérez³⁸, Vicente Torrente Segarra³⁹, CARLOS TAREK SALMAN MONTE⁴⁰, JOSE ELOY OLLER RODRIGUEZ⁴¹ and José María Pego-Reigosa⁴², ¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²Hospital Sierrallana, Santander, Spain, ³Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁴Buenos Aires Instituto, West Reading, CA, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Universitario Donostia, San Sebastian, Spain, ¹⁶⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁹University Clinical Hospital of Canarias, Tenerife, Spain, ²⁰Son Llàtzer University Hospital, Palma de Mallorca, Spain, ²¹Hospital Sierrallana, CANTABRIA, Spain, ²²Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Hospital Ramón y Cajal, Madrid, Spain, ²⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁶Virgen Macarena University Hospital,, Sevilla, Spain, ²⁷Hospital Insular de Gran Canaria, Las palmas, ²⁸Hospital León, LEON, Castilla y Leon, Spain, ²⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ³²Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Infanta Sofia Hospital, Madrid, Spain, ³⁵Hospital Clínico Universitario Virgen de la Arrixaca,, Murcia, Spain, ³⁶La Paz University Hospital, Alcalá De Henares, Spain, ³⁷SERV. REUMATOLOGIA, Lugo, Spain, ³⁸Complejo Hospitalario de Orense, Santiago de Composte, Spain, ³⁹Hospital Comarcal del Alt Penedes, Madrid, Spain, ⁴⁰Hospital del Mar, Barcelona, Spain, ⁴¹HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁴²Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].